loading...| Preferred Name |
methylnaltrexone |
|
| Synonyms |
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium |
|
| Definitions |
A methyl derivative of noroxymorphone with selective, opioid-receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, resulting in decreases in opioid-related constipation, urinary retention, and pruritis, respectively. Methylnaltrexone does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48403" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48403" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000437863 |
|
| altLabel |
17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxy-17-methyl-6-oxomorphinanium MNTX N-methylnaltrexone bromide |
|
| cui |
C0066411 C2343921 |
|
| DATE FIRST PUBLISHED |
2005-06-25 |
|
| Date last modified |
2006-08-29 |
|
| definition |
A methyl derivative of noroxymorphone with selective, opioid-receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, resulting in decreases in opioid-related constipation, urinary retention, and pruritis, respectively. Methylnaltrexone does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C48403" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C48403" NCI Thesaurus) |
|
| NCI ID |
C48403 |
|
| notation |
CDR0000437863 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
methylnaltrexone |
|
| tui |
T109 T121 |